中危非肌层浸润性膀胱癌:国际膀胱癌组织更新的共识定义与管理推荐
国际膀胱癌组织(IBCG)基于2022年1月前发表的随机临床试验、荟萃分析、系统综述和临床实践指南进行协作综述,更新中危非肌层浸润性膀胱癌(IR NMIBC)的共识定义与管理推荐。IBCG推荐将IR NMIBC定义为复发性、多发性或大小≥3 cm的TaLG肿瘤,或任何T1LG肿瘤;若采用3级分级系统,则任何TaG2肿瘤无论新发或复发均视为IR。管理应基于多发性肿瘤、早期复发(<1年)、频繁复发(>1次/年)、肿瘤大小(≥3 cm)和既往膀胱内治疗失败等风险因素进行分层。
要点
- IBCG推荐IR NMIBC定义为复发性、多发性或≥3 cm的TaLG肿瘤,或任何T1LG肿瘤。
- 若采用3级分级系统,任何TaG2肿瘤无论新发或复发均视为IR疾病。
- 无风险因素者最佳管理为单次术后膀胱内化疗。
核心结论
- 标准化IR NMIBC的定义对患者适当管理和临床试验结果比较至关重要。
- IBCG推荐IR NMIBC定义为复发性、多发性或≥3 cm的TaLG肿瘤,或任何T1LG肿瘤;若采用3级分级系统,任何TaG2肿瘤无论新发或复发均视为IR疾病。
- 辅助管理应基于已确立的风险因素。
研究设计与样本
- IBCG协作综述,检索PubMed/Medline中2022年1月前发表的关于IR NMIBC的随机临床试验、荟萃分析、系统综述和临床实践指南。
主要发现
- 不同指南对IR NMIBC的定义存在差异。
- 肿瘤的准确分级和分期,尤其是排除高级别/G3疾病和/或原位癌,至关重要。
- IBCG推荐IR NMIBC管理应进一步基于以下风险因素:多发性肿瘤(多于一个)、早期复发(<1年)、频繁复发(>1次/年)、肿瘤大小(≥3 cm)和既往膀胱内治疗失败。
关键数值与推荐
- IBCG推荐IR NMIBC定义为复发性、多发性或大小≥3 cm的TaLG肿瘤,或任何T1LG肿瘤。
- 若采用3级分级系统,任何TaG2肿瘤无论新发或复发均视为IR疾病。
- 无风险因素的患者最佳管理为单次术后膀胱内化疗。
- 有1–2个风险因素的患者应接受额外辅助诱导膀胱内化疗(若既往用过化疗则用BCG)。
- 有3个或以上风险因素的患者应接受诱导加1年维持BCG。
临床怎么用
- 根据风险因素数量对IR NMIBC患者进行分层管理:无风险因素者单次术后膀胱内化疗,1–2个风险因素者额外辅助诱导膀胱内化疗(或BCG),≥3个风险因素者诱导加1年维持BCG。
- BCG不可用或BCG后复发时,推荐替代膀胱内治疗(化疗单药、联合或化疗热灌注)或临床试验。
- 管理前应确保肿瘤准确分级和分期,尤其排除高级别/G3疾病和/或原位癌。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Intermediate-risk (IR) non-muscle-invasive bladder cancer (NMIBC) is a heterogeneous disease. OBJECTIVE: To update the International Bladder Cancer Group (IBCG) guidance and provide practical recommendations on IR NMIBC management. EVIDENCE ACQUISITION: A collaborative review of published randomized clinical trials, meta-analyses, systematic reviews, and clinical practice guidance on IR NMIBC published before January 2022 was undertaken using PubMed/Medline. EVIDENCE SYNTHESIS: Variation exists between guidelines in defining IR NMIBC. The IBCG recommends defining IR NMIBC as any TaLG tumor that is either recurrent or multifocal or has size ≥3 cm, OR any T1LG tumor. If the 3 tier grading system is used, than any TaG2 tumor would also be considered IR diease regardless of whether new diagnosis or recurrent. Accurate grading and staging of tumor, particularly in ruling out HG/G3 disease and/or carcinoma in situ, are crucial. The IBCG recommends that management of IR NMIBC should be further based on the following risk factors: multifocal tumor (more than one), early recurrence (<1 yr), frequent recurrence (>1/yr), tumor size (≥3 cm), and failure of prior intravesical treatment. Patients with no risk factors are best managed by one dose of postoperative intravesical chemotherapy. Patients with one to two risk factors should be offered additional adjuvant induction intravesical chemotherapy (or bacillus Calmette-Guérin (BCG) if prior chemotherapy has been used). Patients with three or more risk factors should be offered induction plus 1-yr maintenance BCG. Where BCG is not available or recurrent disease following BCG is present, alternative intravesical treatments such as chemotherapy (single agent, combination, or chemohyperthermia) or a clinical trial are recommended. CONCLUSIONS: Standardizing the definition of IR NMIBC is critical for appropriate management of patients and for allowing a comparison of outcomes across clinical trials. The IBCG recommends defining IR NMIBC as any TaLG tumor that is either recurrent or multifocal or ≥3 cm, OR any T1LG tumor. If the 3 tier grading system is used, than any TaG2 tumor would also be considered IR disease regardless of whether new diagnosis or recurrent. Adjunctive management should then be based on established risk factors. PATIENT SUMMARY: Standardizing the definition of intermediate-risk (IR) non-muscle-invasive bladder cancer (NMIBC), which is a heterogeneous disease, is critical for appropriate management of patients. The International Bladder Cancer Group recommends classification of IR NMIBC tumors and personalized management based on the following risk factors: multifocal tumor (more than one), early recurrence (<1 yr), frequent recurrence (>1/yr), tumor size (≥3 cm), and previous intravesical treatment.
引用
- Tan WS, Steinberg G, Witjes JA, et al. Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group. Eur Urol Oncol. 2022. PMID: 35718695. doi:10.1016/j.euo.2022.05.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。